THE OPSONIC ANTIBODY-RESPONSE OF FEMALE RATS TO TYPE-III GROUP-B STREPTOCOCCAL IMMUNIZATION - A MODEL FOR MATERNAL IMMUNITY

被引:1
作者
HEIMAN, HS [1 ]
WEISMAN, LE [1 ]
机构
[1] WALTER REED ARMY MED CTR,DEPT PEDIAT,WASHINGTON,DC 20307
关键词
D O I
10.1016/0165-2427(90)90079-8
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Group B streptococcus (GBS) remains a major cause of neonatal infection. Maternal immunization-induced GBS antibody may protect neonates from GBS disease. Since the opsonophagocytosis assay correlates well with survival in GBS infected suckling rats, we sought to determine an immunization schedule which would induce type III GBS opsonic antibody in rat dams above a predetermined level of 10 dilution-1 (dil-1). This schedule could then be used for future studies of maternal-fetal immunity. Wistar rat dams (n=12) were given killed GBS type III using three immunization schedules (primary injection, initial booster at 7, 14 or 22 days and then weekly boosters). Opsonic GBS type III antibody and total immunoglobulin (IgG) were measured. Only the schedule with a 7-day initial booster resulted in GBS type-specific opsonic antibody consistently above 10 dil-1. The IgG (467±83 mg/100 ml) remained constant while the opsonic antibody increased significantly to 50 and 63 dil-1 (P<0.01 compared to day 0) after boosters on day 7 and 14 respectively. Eight pregnant dams, who received a primary immunization and boosters at 7 and 14 days, developed GBS type III opsonic antibody titers (72 dil-1) similar to non-pregnant dams and potentially adequate to protect suckling rats from GBS disease. This model may now be used to study other adjuvants, immunogens, and maternal-fetal immunity using established suckling rat models of GBS disease. © 1990.
引用
收藏
页码:79 / 89
页数:11
相关论文
共 27 条
[1]  
BAKER CJ, 1981, PEDIATRICS, V68, P544
[2]   CORRELATION OF MATERNAL ANTIBODY DEFICIENCY WITH SUSCEPTIBILITY TO NEONATAL GROUP-B STREPTOCOCCAL INFECTION [J].
BAKER, CJ ;
KASPER, DL .
NEW ENGLAND JOURNAL OF MEDICINE, 1976, 294 (14) :753-756
[3]   IMMUNOGENICITY OF POLYSACCHARIDES FROM TYPE-III, GROUP-B STREPTOCOCCUS [J].
BAKER, CJ ;
EDWARDS, MS ;
KASPER, DL .
JOURNAL OF CLINICAL INVESTIGATION, 1978, 61 (04) :1107-1110
[4]  
BAKER CJ, 1985, REV INFECT DIS, V7, P458
[5]  
BAKER CJ, 1983, INFECT DIS, P820
[6]  
BINAGHI RA, 1963, J IMMUNOL, V92, P920
[7]   QUANTITATION OF INVITRO OPSONIC ACTIVITY OF HUMAN-ANTIBODY INDUCED BY A VACCINE CONSISTING OF THE TYPE-III-SPECIFIC POLYSACCHARIDE OF GROUP-B STREPTOCOCCUS [J].
DECUENINCK, BJ ;
EISENSTEIN, TK ;
MCINTOSH, TS ;
SHOCKMAN, GD ;
SWENSON, RM .
INFECTION AND IMMUNITY, 1983, 39 (03) :1155-1160
[8]   TYPE-SPECIFIC PROTECTION OF NEONATAL RATS FROM LETHAL GROUP-B STREPTOCOCCAL INFECTION BY IMMUNE SERA OBTAINED FROM HUMAN VOLUNTEERS VACCINATED WITH TYPE-III-SPECIFIC POLYSACCHARIDE [J].
DECUENINCK, BJ ;
EISENSTEIN, TK ;
MCINTOSH, TS ;
SHOCKMAN, GD ;
SWENSON, RM .
INFECTION AND IMMUNITY, 1982, 37 (03) :961-965
[9]   QUANTITATIVE-DETERMINATION IN HUMAN-SERA OF VACCINE-INDUCED ANTIBODY TO TYPE-SPECIFIC POLYSACCHARIDES OF GROUP-B STREPTOCOCCI USING AN ENZYME-LINKED IMMUNOSORBENT-ASSAY [J].
EISENSTEIN, TK ;
DECUENINCK, BJ ;
RESAVY, D ;
SHOCKMAN, GD ;
CAREY, RB ;
SWENSON, RM .
JOURNAL OF INFECTIOUS DISEASES, 1983, 147 (05) :847-856
[10]   SUMMARY OF THE NATIONAL-INSTITUTES-OF-HEALTH WORKSHOP ON GROUP-B STREPTOCOCCAL INFECTION [J].
FISCHER, G ;
HORTON, RE ;
EDELMAN, R .
JOURNAL OF INFECTIOUS DISEASES, 1983, 148 (01) :163-166